CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries...
CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) today announced that Dr. David...
CARMIEL, Israel, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical...
CARMIEL, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the first...
CARMIEL, Israel, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered...
CARMIEL, Israel, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that Yossi Maimon...
CARMIEL, Israel, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Yossi Maimon, the...
NEW YORK and CARMIEL, Israel, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX...
CARMIEL, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that is has...
CARMIEL, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that Dr. David Aviezer...
CARMIEL, Israel, Aug. 13, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has received...
CARMIEL, Israel, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) announced today that Yossi Maimon, the...
By Kristin Jones Protalix BioTherapeutics Inc. (PLX) has received a $25 million milestone payment from Pfizer Inc. (PFE) after the U.S. Food and...
The U.S. Food and Drug Administration on Tuesday approved a new treatment developed by Protalix BioTherapeutics Inc. (PLX, PLX.TV) for adults with...
The Food and Drug Administration Tuesday approved a new treatment developed by Protalix Bio Therapeutics Inc. (PLX, PLX.TV) for adults with a type...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads